Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomised Controlled Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction (CLAD)

NCT02709343 is registered in ClinicalTrials.gov with The University of Queensland as lead sponsor.

NCT NCT02709343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02709343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomised Controlled Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction (CLAD)
Lead sponsor
The University of Queensland
Phase
Phase 2
Overall status
Completed
Start date
April 21, 2017
Completion date
October 25, 2023
Enrollment
64 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lung allograft dysfunction (clad)